What’s my big wish as we all move forward with pandemic life in 2022? To live in a world with better communication skills. Specifically, to improve how we listen to each other. Because from where I sit, there’s a whole lot of telling going on and not enough waiting to…
A Lief Cares initiative, under its partnership with AxeALS, raised nearly $8,000 for the amyotrophic lateral sclerosis (ALS) community and is providing patients with specially formulated nutritional supplements. Lief Cares is the nonprofit donation program of the California-based formulation and product developer and dietary supplement manufacturer Lief Labs. Through…
Prilenia Therapeutics announced the completion of patient enrollment in the pridopidine arm of the HEALEY ALS platform trial, the first study to simultaneously test multiple experimental therapies for amyotrophic lateral sclerosis (ALS). Prilenia’s oral therapy pridopidine was selected as the trial’s fourth regimen (NCT04615923), with…
Amylyx Pharmaceuticals has filed an application with the European Medicines Agency seeking the approval of its lead candidate AMX0035 as a treatment of amyotrophic lateral sclerosis (ALS), the company announced in a press release. The marketing authorization request follows similar submissions to Health Canada and…
On New Year’s Eve, I took our kids and their friends bowling. My husband, Todd, who has ALS and is paralyzed, stayed home and used his computer. As we arrived at the bowling alley, I received a text from Todd saying that he needed my help with his…
A recent tweet by an Australian amyotrophic lateral sclerosis (ALS) patient using an implantable brain computer interface called Stentrode is said to be the first time a message has been posted on social media with the help of such technology. By using this brain computer interface, developed by…
“Mirror in the bathroom Please talk free The door is locked Just you and me.” The time for annual resolutions to be implemented has arrived. The most impactful betterment plans arise from an honestly objective self-review. What more appropriate figurative…
An investigational antisense oligonucleotide (ASO) molecule that works by increasing the production of Stathmin-2 protein effectively reversed a number of neurodegenerative processes in lab-grown motor neurons, the cells that are damaged in amyotrophic lateral sclerosis (ALS), a study found. The rescue occurred even in the absence of TDP-43, a…
Anyone up for setting their New Year’s resolutions? Not me. Normally, I’d use these days in January to conjure up resolutions, create new daily routines, and set personal goals for the year ahead. But after the past two years of roller-coaster events that blew holes in my resolutions, I feel…
The U.S. Food and Drug Administration (FDA) has accepted for review Amylyx Pharmaceuticals‘ application seeking approval of AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). The new drug application (NDA) also was granted priority review by the regulatory agency, which reduces review time from the standard…
Get regular updates to your inbox.
